CN110248646A - 包含吡非尼酮的缓释组合物用于治疗和逆转人脂肪性肝炎(nafld/nash)的药物用途 - Google Patents

包含吡非尼酮的缓释组合物用于治疗和逆转人脂肪性肝炎(nafld/nash)的药物用途 Download PDF

Info

Publication number
CN110248646A
CN110248646A CN201780076430.3A CN201780076430A CN110248646A CN 110248646 A CN110248646 A CN 110248646A CN 201780076430 A CN201780076430 A CN 201780076430A CN 110248646 A CN110248646 A CN 110248646A
Authority
CN
China
Prior art keywords
pharmaceutical composition
pirfenidone
liver
nafld
nash
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780076430.3A
Other languages
English (en)
Chinese (zh)
Inventor
J.S.阿门达里兹博伦达
J.A.R.马加纳卡斯特罗
N.赫南德兹阿尔达纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Therapy and Technology SA de CV
Original Assignee
Cell Therapy and Technology SA de CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapy and Technology SA de CV filed Critical Cell Therapy and Technology SA de CV
Priority to CN202211265065.XA priority Critical patent/CN115969802A/zh
Publication of CN110248646A publication Critical patent/CN110248646A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201780076430.3A 2016-11-11 2017-11-09 包含吡非尼酮的缓释组合物用于治疗和逆转人脂肪性肝炎(nafld/nash)的药物用途 Pending CN110248646A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211265065.XA CN115969802A (zh) 2016-11-11 2017-11-09 含吡非尼酮缓释组合物用于治疗和逆转人脂肪性肝炎的药物用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MXMX/A/2016/014775 2016-11-11
MX2016014775A MX364040B (es) 2016-11-11 2016-11-11 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
PCT/MX2017/000129 WO2018088886A1 (es) 2016-11-11 2017-11-09 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211265065.XA Division CN115969802A (zh) 2016-11-11 2017-11-09 含吡非尼酮缓释组合物用于治疗和逆转人脂肪性肝炎的药物用途

Publications (1)

Publication Number Publication Date
CN110248646A true CN110248646A (zh) 2019-09-17

Family

ID=61193005

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780076430.3A Pending CN110248646A (zh) 2016-11-11 2017-11-09 包含吡非尼酮的缓释组合物用于治疗和逆转人脂肪性肝炎(nafld/nash)的药物用途
CN202211265065.XA Pending CN115969802A (zh) 2016-11-11 2017-11-09 含吡非尼酮缓释组合物用于治疗和逆转人脂肪性肝炎的药物用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211265065.XA Pending CN115969802A (zh) 2016-11-11 2017-11-09 含吡非尼酮缓释组合物用于治疗和逆转人脂肪性肝炎的药物用途

Country Status (21)

Country Link
US (3) US20190262325A1 (enExample)
EP (1) EP3539537A1 (enExample)
JP (2) JP2019535822A (enExample)
KR (2) KR20190084056A (enExample)
CN (2) CN110248646A (enExample)
AR (1) AR110057A1 (enExample)
AU (2) AU2017358367B2 (enExample)
CA (1) CA3043300A1 (enExample)
CL (1) CL2019001280A1 (enExample)
CO (1) CO2019004799A2 (enExample)
EC (1) ECSP19031851A (enExample)
IL (1) IL266519A (enExample)
JO (1) JOP20190102A1 (enExample)
MA (1) MA45754A1 (enExample)
MX (1) MX364040B (enExample)
PE (1) PE20191149A1 (enExample)
PH (1) PH12019501047A1 (enExample)
RU (1) RU2019116422A (enExample)
UY (1) UY37478A (enExample)
WO (1) WO2018088886A1 (enExample)
ZA (1) ZA201903012B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117007806A (zh) * 2023-09-21 2023-11-07 中国人民解放军军事科学院军事医学研究院 靶向肝巨噬细胞内lxr用于控制慢乙肝进展

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
EP3716975A4 (en) * 2017-11-28 2022-01-12 Eiger Biopharmaceuticals, Inc. METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
WO2020115774A1 (en) 2018-12-06 2020-06-11 Cipla Limited High drug load extended release formulations
EP4232063A4 (en) * 2020-10-23 2025-01-01 HAN, Hq BIFUNCTIONAL ANTAGONISTS OF TUMOR NECROSIS FACTOR-ALPHA AND TRANSFORMING GROWTH FACTOR-BETA AND THEIR USES

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1356816A1 (en) * 2001-01-29 2003-10-29 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
WO2005000227A2 (en) * 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
CN1701793A (zh) * 2004-05-24 2005-11-30 上海睿星基因技术有限公司 吡非尼酮治疗肝损伤坏死和急性肺损伤的用途
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
CN102209543A (zh) * 2008-11-10 2011-10-05 英特芒尼公司 用于具有非典型肝功能的患者的吡非尼酮治疗
CN102488660A (zh) * 2011-12-15 2012-06-13 西安天一秦昆制药有限责任公司 一种含吡非尼酮的缓释微丸
CN103550242A (zh) * 2013-11-22 2014-02-05 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法
CN103957892A (zh) * 2011-07-19 2014-07-30 细胞治疗技术合伙股份有限公司 以缓释片剂形式制备含有吡非尼酮的药物组合物的方法及其在人慢性肾功能衰竭、乳房包膜挛缩和肝纤维化的复原中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010048716A1 (en) * 2008-10-29 2010-05-06 Pacific Therapeutics Ltd. Composition and method for treating fibrosis

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1356816A1 (en) * 2001-01-29 2003-10-29 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
WO2005000227A2 (en) * 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
CN1701793A (zh) * 2004-05-24 2005-11-30 上海睿星基因技术有限公司 吡非尼酮治疗肝损伤坏死和急性肺损伤的用途
CN102209543A (zh) * 2008-11-10 2011-10-05 英特芒尼公司 用于具有非典型肝功能的患者的吡非尼酮治疗
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
CN103957892A (zh) * 2011-07-19 2014-07-30 细胞治疗技术合伙股份有限公司 以缓释片剂形式制备含有吡非尼酮的药物组合物的方法及其在人慢性肾功能衰竭、乳房包膜挛缩和肝纤维化的复原中的应用
CN102488660A (zh) * 2011-12-15 2012-06-13 西安天一秦昆制药有限责任公司 一种含吡非尼酮的缓释微丸
CN103550242A (zh) * 2013-11-22 2014-02-05 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HIDEKI NAKANISHI ET AL.,: "Pirfenidone inhibits the induction of iNOS stimulated by interleukin-1beta at a step of NF-kappaB DNA binding in hepatocytes", 《J HEPATOL》 *
J. MAC´IAS-BARRAG´AN ET AL.,: "5-METHYL-1-PHENYL-2-(1H)-PYRIDONE TREATMENT IMPROVES MARKERS OF HEPATIC FUNCTION AND FIBROSIS IN STEATOSIS NDUCED BY HIGH FAT/CARBOHYDRATE DIET", 《JOURNAL OF HEPATOLOGY》 *
MACIAS-BARRAGAN J ET AL.,: "Pirfenidone LP activates PPARa and LXRa and results in decreased expression of proinflammatory cytokines and improvement of NASH features induced by high fat/carbohydrate diet", 《HEPATOLOGY》 *
OSMAN N OZES ET AL.,: "PRECLINICAL ACTIVITY OF PIRFENIDONE (5-METHYL-1PHENYL-2(IH)-PYRIDONE) IN CELL-BASED MODELS OF NONALCOHOLIC STEATOHEPATITIS", 《HEPATOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117007806A (zh) * 2023-09-21 2023-11-07 中国人民解放军军事科学院军事医学研究院 靶向肝巨噬细胞内lxr用于控制慢乙肝进展

Also Published As

Publication number Publication date
AR110057A1 (es) 2019-02-20
CL2019001280A1 (es) 2019-07-19
KR20190084056A (ko) 2019-07-15
IL266519A (en) 2019-07-31
AU2024200737A1 (en) 2024-02-22
JP2019535822A (ja) 2019-12-12
EP3539537A1 (en) 2019-09-18
AU2017358367A1 (en) 2019-05-30
MX364040B (es) 2019-04-11
PH12019501047A1 (en) 2019-12-11
ZA201903012B (en) 2020-09-30
RU2019116422A (ru) 2020-12-11
AU2017358367B2 (en) 2023-11-09
US20250325530A1 (en) 2025-10-23
JP2022173344A (ja) 2022-11-18
CA3043300A1 (en) 2018-05-17
US20230181550A1 (en) 2023-06-15
ECSP19031851A (es) 2019-06-30
MA45754A1 (fr) 2019-12-31
US20190262325A1 (en) 2019-08-29
PE20191149A1 (es) 2019-09-02
JOP20190102A1 (ar) 2019-05-06
RU2019116422A3 (enExample) 2021-04-09
CN115969802A (zh) 2023-04-18
WO2018088886A1 (es) 2018-05-17
CO2019004799A2 (es) 2019-07-31
KR20240065330A (ko) 2024-05-14
UY37478A (es) 2018-05-31
MX2016014775A (es) 2018-05-10

Similar Documents

Publication Publication Date Title
CN110248646A (zh) 包含吡非尼酮的缓释组合物用于治疗和逆转人脂肪性肝炎(nafld/nash)的药物用途
US20200222470A1 (en) Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria
Wang et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes
Liu et al. Andrographolide sulfonate ameliorates experimental colitis in mice by inhibiting Th1/Th17 response
JP7161731B2 (ja) 疾患及び障害の処置及び予防のための短鎖脂肪酸の使用
Chen et al. Glycyrrhizin ameliorates experimental colitis through attenuating interleukin-17-producing T cell responses via regulating antigen-presenting cells
CN109481684A (zh) 以Optineurin为靶点在制备防治自身免疫性疾病药物中的应用
Guan et al. FDCA attenuates Neuroinflammation and brain injury after cerebral ischemic stroke
Shao et al. DPP‐4 inhibitor linagliptin ameliorates imiquimod‐induced psoriasis‐like skin alterations in type 2 diabetic mice by inhibiting the MAPK/NF‐κB inflammatory pathway
Xu et al. Lysophosphatidic acid increases SLC26A3 expression in inflamed intestine and reduces diarrheal severity in C57BL/6 mice with dextran-sodium-sulfate-induced colitis
JP2021527669A (ja) 線維症の軽減又は治療のための組成物及び方法
CN115737641B (zh) 纯绿青霉醇在制备治疗炎症性肠病药物中的应用
CN104411309A (zh) 阿可拉定在制备用于治疗原发性肝癌的药物中的用途
CN110870877A (zh) 戈氏副拟杆菌用于制备治疗慢性肾脏疾病的医药组合物的用途
US20250152664A1 (en) Compositions and methods for treating metabolic disorders
Jayabal et al. Association of serum uric acid level and body mass index between non-alcoholic fatty liver disease patients and healthy volunteers
Askar et al. A Histological Study of The Protective Role of Intermittent Fasting and Probiotics on Indomethacin Induced Colitis in Adult Male Albino Rats.
Hamam et al. Effect of pirfenidone on cardiac complications in a model of Kawasaki disease in female Balb/C Mice: Histological and Immunohistochemical study
Tjokroprawiro et al. Testosteron Level and Insulin Resistance in Men With Type 2 Diabetes Mellitus-Metabolic Syndrome
JPWO2020130003A1 (ja) 炎症性疾患およびアレルギー性疾患の治療、予防または改善剤
ROSSI DAVID A. DORWARD| CHRISTOPHER D. LUCAS I KEITH C. ALLEN I ADRIANO G. ROSSI
WO2019189676A1 (ja) ヒアルロン酸を有効成分として含むアレルゲン作用増強剤
CN111032030A (zh) 氯硝柳胺乙醇胺盐在制备治疗系统性红斑狼疮及其并发症的药物中的应用
Gulati et al. T1713 Genetic Factors Affecting Murine Intestinal Antimicrobial Peptide Expression
Tanabe et al. T1715 Precursor Processing of Human Defensin-5 Is Essential for the Treatment of Mouse Colitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190917

RJ01 Rejection of invention patent application after publication